Regulatory Updates
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 1–12 of 379 articles
Quick answer
NovaPharmaNews Regulatory Updates hub for FDA covers 379 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA adds bemotrizinol to sunscreen rules, expanding U.S. UV filter options
Biotech coming of age: market analysis of a sector in transition
FDA approves Vepdegestrant (Veppanu) for ESR1-mutated breast cancer
Sensorion pivots to SENS-601 after Regeneron’s OTOF hearing loss advance
SLS Stock Jumps on Biotech Momentum as SELLAS Gains 25.10%
Medicare GLP-1 coverage 2026: Bridge program starts July 1
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria
FDA Drug Approval: What Approval Means for Pharma Marketing and BD
Vanda tradipitant update: FDA re-review extends to Dec. 5, 2025
Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability
FDA Approves Lumasiran for PH1: What BD and Investors Should Know
Manufacturing pipeline approvals: what the evidence confirms
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.